After first FDA win last year, Ascendis touts a new PhIII success in hypoparathyroidism
After achieving its first FDA approval last summer, Ascendis Pharma believes it’s approaching a second in the near future.
The Danish biotech touted topline Phase III data for a hypoparathyroidism program Sunday evening, saying it met the primary endpoint and all key secondary endpoints. As such, the company plans to submit an NDA in the third quarter and also file for European approval by the end of the year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.